FP
ALXN

Foundry Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Foundry Partners’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-49,835
Closed -$6.62M – 306
2013
Q4 		$6.62M Buy
+49,835
New +$5.98M 0.59% 66

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Foundry Partners's ALXN Position: Q1 2014 in Review

Foundry Partners sold out of Alexion Pharmaceuticals (ALXN) in Q1 2014, closing a stake of 49,835 shares — an estimated $6.62M sold.

Foundry Partners first reported a position in ALXN in Q4 2013 and held it in 1 quarter. The position peaked at $6.62M in Q4 2013. 504 funds tracked by Wall St. Rank hold ALXN as of Q1 2014.

  • Foundry Partners reported no remaining Alexion Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
  • Foundry Partners sold 49,835 Alexion Pharmaceuticals shares in Q1 2014, an estimated $6.62M.
  • Foundry Partners first reported a position in Alexion Pharmaceuticals in Q4 2013 and held it in 1 quarter.
  • Foundry Partners's Alexion Pharmaceuticals position peaked at $6.62M in Q4 2013.
  • 504 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2014.

Based on Foundry Partners's 13F filing for Q1 2014, filed 14 Apr 2014.